SB Life Science is led by Dr. Toshihiro Nakada and Mr. Joseph Chow.
Toshihiro Nakada M.D.
Dr. Nakada has actively invested and managed health care companies including drug discovery, hospitals and medical devices for over ten years. Dr. Nakada was formerly Director of Strategic Planning at SOFTBANK, where he managed overall corporate strategy and public/private equity investments for SOFTBANK. Dr. Nakada has extensive experience in industry, as a consultant at Boston Consulting Group where he managed wide range of projects such as research and development strategy, portfolio management, mergers and acquisition strategy, and developing drug pricing policies for global life science companies. Dr. Nakada has also worked as a clinician for the hospital affiliated with the Keio University Medical School and related hospitals. Dr. Nakada received a M.D. from Chiba University in Japan as well as an M.B.A. from the M.I.T. Sloan School of Management.
Mr. Chow was formerly President of Singapore Bio-Innovations, a life sciences-focused venture capital fund set up by the Singapore government in 1990. Mr. Chow has over ten years of venture capital experience in the biotech industry. His notable early-stage investments while at Singapore Bio-Innovations included Affymetrix, Tularik, Aclara, Lynx, Dendreon, Tanox, Combichem, Therion, Metrika, and ISTA. Mr. Chow has been an active board member of Optimer Pharmaceuticals, geneticXchange and U-Systems and board observer of Kadmus Pharmaceuticals. Mr. Chow completed his undergraduate studies at U.C. Berkeley and received a M.Sc. in biochemical engineering from M.I.T. as well as an M.B.A. in finance from the M.I.T. Sloan School of Management.